{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T18:45:24Z","timestamp":1782326724797,"version":"3.54.5"},"reference-count":31,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,12,1]]},"DOI":"10.2169\/internalmedicine.1222-22","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T22:28:46Z","timestamp":1701383326000},"page":"3525-3530","source":"Crossref","is-referenced-by-count":3,"title":["Pembrolizumab-induced Myopathy with Anti-striated Muscle Antibodies Successfully Treated by Plasma Exchange"],"prefix":"10.2169","volume":"62","author":[{"given":"Sunao","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Neurology, JA Toride Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Okabayashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, JA Toride Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsuki","family":"Soejima","sequence":"additional","affiliation":[{"name":"Department of Neurology, JA Toride Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Oniki","sequence":"additional","affiliation":[{"name":"Department of Neurology, JA Toride Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Neurology, JA Toride Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tomimitsu","sequence":"additional","affiliation":[{"name":"Department of Neurology, JA Toride Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Makker V, Colombo N, Herr\u00e1ez AC, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 386: 437-448, 2022.","DOI":"10.1056\/NEJMoa2108330"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Marini A, Bernardini A, Gigli GL, et al. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96: 754-766, 2021.","DOI":"10.1212\/WNL.0000000000011795"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39: 4073-4126, 2021.","DOI":"10.1200\/JCO.21.01440"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hamada N, Maeda A, Takase-Minegishi K, et al. Incidence and distinct features of immune checkpoint inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis. Front Immunol 12: 803410, 2021.","DOI":"10.3389\/fimmu.2021.803410"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Aldrich J, Pundole X, Tummala S, et al. Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors. Arthritis Rheumatol 73: 866-874, 2021.","DOI":"10.1002\/art.41604"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ono R, Iwai Y, Yamazaki T, et al. Nivolumab-induced myositis and myocarditis with positive anti-titin antibody and anti-voltage-gated potassium channel Kv1.4 antibody: a case report. Intern Med 61: 2973-2979, 2022.","DOI":"10.2169\/internalmedicine.8772-21"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167-3175, 2010.","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7: 319, 2019.","DOI":"10.1186\/s40425-019-0774-y"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Wang Y, Huan X, Jiao K, et al. Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: a prospective cohort study. Clin Immunol 241: 109058, 2022.","DOI":"10.1016\/j.clim.2022.109058"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Schiopu SRI, K\u00e4smann L, Sch\u00f6nermarck U, et al. Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy - case report. Transl Lung Cancer Res 10: 1039-1046, 2021.","DOI":"10.21037\/tlcr-20-1095"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Shirai T, Kiniwa Y, Sato R, et al. Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody. Eur J Cancer 106: 193-195, 2019.","DOI":"10.1016\/j.ejca.2018.10.025"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Zimmer L, Goldinger SM, Hogmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60: 210-225, 2016.","DOI":"10.1016\/j.ejca.2016.02.024"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Takahashi S, Mukohara S, Hatachi S, et al. A case of myositis with dropped head syndrome and anti-titin antibody positivity induced by pembrolizumab. Scand J Rheumatol 49: 509-511, 2020.","DOI":"10.1080\/03009742.2020.1760346"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Haddox CL, Shenoy N, Shah KK, et al. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol 28: 673-675, 2017.","DOI":"10.1093\/annonc\/mdw655"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kee W, Ng KYY, Lee JJX, et al. Myasthenia gravis and myocarditis after administration of pembrolizumab in a patient with metastatic non-small cell lung cancer and resected thymoma. Clin Lung Cancer 23: e293-e295, 2022.","DOI":"10.1016\/j.cllc.2021.12.001"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Onda A, Miyagawa S, Takahashi N, et al. Pembrolizumab-induced ocular myasthenia gravis with anti-titin antibody and necrotizing myopathy. Intern Med 58: 1635-1638, 2019.","DOI":"10.2169\/internalmedicine.1956-18"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sekiguchi K, Hashimoto R, Noda Y, et al. Diaphragm involvement in immune checkpoint inhibitor-related myositis. Muscle Nerve 60: E23-E25, 2019.","DOI":"10.1002\/mus.26640"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tahir N, Mahboob A, Piao X, et al. Nivolumab, a double-edged sword: a case report of nivolumab-induced myasthenia gravis. J Med Cases 12: 424-428, 2021.","DOI":"10.14740\/jmc3783"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ng AH, Molinares DM, Ngo-Huang AT, Bruera E. Immunotherapy-related skeletal muscle weakness in cancer patients: a case series. Ann Palliat Med 10: 2359-2365, 2021.","DOI":"10.21037\/apm-20-454"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ono R, Iwai R, Yamazaki T, et al. Nivolumab-induced myositis and myocarditis with positive anti-titin antibody and anti-voltage-gated potassium channel Kv1.4 antibody: a case Report. Intern Med 61: 2973-2979, 2022.","DOI":"10.2169\/internalmedicine.8772-21"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Fazel M, Jedlowski PM. Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma. Case Rep Immunol 2019: 2539493, 2019.","DOI":"10.1155\/2019\/2539493"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Bilen MA, Subudhi S, Gao J, et al. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 4: 36, 2016.","DOI":"10.1186\/s40425-016-0139-8"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Norwood TG, Westbrook BC, Johnson DB, et al. Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer 5: 91, 2017.","DOI":"10.1186\/s40425-017-0296-4"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Thakolwiboon S, Karukote A, Wilms H, et al. <i>De novo<\/i> myasthenia gravis induced by atezolizumab in a patient with urothelial carcinoma. Cureus 11: e5002, 2019.","DOI":"10.7759\/cureus.5002"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Jeyakumar N, Etchegaray M, Henry J, et al. The terrible triad of checkpoint inhibition: a case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma. Case Rep Immunol 2020: 5126717, 2020.","DOI":"10.1155\/2020\/5126717"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Miller RG, Milner-Brown HS, Mirka A, et al. Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology 36: 729-732, 1986.","DOI":"10.1212\/WNL.36.5.729"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Sanders DB, Worfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87: 419-425, 2016.","DOI":"10.1212\/WNL.0000000000002790"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Shi J, Tan Y, Huang Y, et al. Association between clinical factors and result of immune checkpoint inhibitor related myasthenia gravis: a single center experience and systematic review. Front Neurol 13: 858628, 2022.","DOI":"10.3389\/fneur.2022.858628"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Kamo H, Hatano T, Kanai K, et al. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report. BMC Neurol 19: 184, 2019.","DOI":"10.1186\/s12883-019-1416-1"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Seki M, Uruha A, Ohnuki Y, et al. Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun 100: 105-113, 2019.","DOI":"10.1016\/j.jaut.2019.03.005"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Sugiyama Y, Esa Y, Watanabe A, et al. Immune checkpoint inhibitor-induced anti-striational antibodies in myasthenia gravis and myositis: a case report. Rinsho Shinkeigaku (Clin Neurol) 61: 630-634, 2021 (in Japanese, Abstract in English).","DOI":"10.5692\/clinicalneurol.cn-001604"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/23\/62_1222-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T03:19:50Z","timestamp":1701487190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/23\/62_1222-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":31,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1222-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"article-number":"1222-22"}}